For weight management , certain GLP-1 formulations (liraglutide 3.0mg [Saxenda] and semaglutide 2.4mg [Wegovy]) are licensed for chronic weight management in adults with: BMI 30 kg/m , or BMI 27 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or dyslipidaemia) However, NHS access to these medications for weight management is typically restricted to specialist tier 3 or tier 4 weight management services, with specific eligibility criteria defined by NICE technology appraisals (TA494 for liraglutide, TA664 for semaglutide) and local commissioning arrangements
Patients with pre-existing heart conditions, hypertension, or family history of cardiac disease should discuss semaglutide use with their primary care physician before starting treatment to establish a baseline and monitoring plan
Yes, tirzepatide significantly reduces appetite by acting on brain areas that control hunger and slowing gastric emptying, leading to reduced food cravings, diminished interest in eating, and feeling satisfied with smaller portions
The coprimary end points for SURMOUNT1 and SURMOUNT2 are mean percentage change in body weight and the percentage of study participants achieving 5% body weight reduction from randomization to 72 weeks
Weight Loss Approvals & Timeline Weight loss drugs have come a long way from banned amphetamines to GLP-1 blockbusters like Wegovy & Zepbound
Your surgical team needs clear communication about your medication schedule, and PlexusDx works with your healthcare providers to ensure proper timing for stopping and restarting your injections around your procedure date
